Synthesis and biological evaluation of a new series of 1, 2, 4-triazolo[1, 5-α]-1, 3, 5-triazines as human a 2a adenosine receptor antagonists with improved water solubility

Journal of Medicinal Chemistry

Volumn 54, Issue 3, 2011, Pages 877-889

  Federico, Stephanie ^a   Paoletta, Silvia ^b   Cheong, Siew Lee ^c   Pastorin, Giorgia ^c   Cacciari, Barbara ^d   Stragliotto, Stefano ^b   Norbert Klotz, Karl ^e   Siegel, Jeffrey ^f   Gao, Zhan Guo ^f   Jacobson, Kenneth A ^f   Moro, Stefano ^b   Spalluto, Giampiero ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d UNIVERSITY OF FERRARA   (Italy)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 7 AMINO 5 (AMINOMETHYL)CYCLOHEXYLMETHYL AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO [1,5 A] 1,3,5 TRIAZINE TRIFLUOROACETATE; 7 AMINO 5 [(8 AMINO)TRIETHYLENOXY] AMINO 2(2 FURYL) 1,2,4 TRIAZOLO [1,5 A] 1,3,5 TRIAZINE TRIFLUOROACETATE; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; RECEPTOR SUBTYPE; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG; URETHAN DERIVATIVE;

ARTICLE; CRYSTAL STRUCTURE; HYDROPHOBICITY; NONHUMAN; PHYSICAL CHEMISTRY; SOLUBILITY; STRUCTURE ACTIVITY RELATION; WASTE; X RAY;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; CRYSTALLOGRAPHY, X-RAY; HEK293 CELLS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; RADIOLIGAND ASSAY; SOLUBILITY; STATIC ELECTRICITY; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZINES; TRIAZOLES; WATER;

EID: 79851495268     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm101349u     Document Type: Article

References (54)

1. Fredholm, B. B.; Arslan, G.; Halldner, L.; Kull, B.; Schulte, G.; Wasserman, W. Structure and function of adenosine receptors and their genes. Nauyn-Schmiedeberrg's Arch. Pharmiacol. 2000, 362, 364-374.
2. Downey, J. M.; Cohen, M. V.; Ytrehus, K.; Liu, Y. Cellular mechanisms in ischemic preconditioning: the role of adenosine and protein kinase Ca. Ann. N.Y. Acad. Sci. 1994, 723, 82-98. (Pubitemid 24228137)
3. 2B receptor. Mol. Pharmacol. 1997, 52, 846-860. (Pubitemid 27484178)
4. Jacobson, K. A.; von Lubitz, D. K. J. E.; Daly, J. W.; Fredholm, B. B. Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol. Sci. 1996, 17, 108-113. (Pubitemid 26112796)
5. Fredholm, B. B. Adenosine and neuroprotection. Int. Rev. Neuro-biol. 1997, 40, 259-280. (Pubitemid 126839964)
6. Feoktistov, I.; Polosa, R.; Holgate, S. T.; Biaggioni, I. Adenosine A2B receptors: a novel therapeutic target in asthma? Trends Pharmacol. Sci. 1998, 19, 148-153. (Pubitemid 28218538)
7. Fozard, J. R.; McCarthy, C. Adenosine receptor ligands as potential therapeutics in asthma. Curr. Opin. Invest. Drugs 2002, 3, 69-77. (Pubitemid 34552307)
8. Richardson, P. J.; Kase, H.; Jenner, P. G. Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol. Sci. 1997, 18, 338-344. (Pubitemid 27404661)
9. Ribeiro, J. A.; Sebastiao, A. M.; de Mendonca, A. Adenosine receptors in the nervous system: pathophysiological implications. Prog. Neurobiol. 2002, 68, 377-392. (Pubitemid 36165128)
10. Yan, L.; Burbiel, J. C.; Maass, A.; Muller, C. E. Adenosine receptor agonists: from basic medicinal chemistry to clinical development. Expert Opin. Emerg. Drugs 2003, 8, 537-576. (Pubitemid 37522665)
11. Fredholm, B. B. Adenosine receptors as targets for drug development. Drug News Perspect. 2003, 16, 283-289. (Pubitemid 37176216)
12. 3 adenosine receptor as an example. Trends Pharmacol. Sci. 2005, 26, 44-51. (Pubitemid 40052709)
13. Fredholm, B. B.; IJzerman, A. P.; Jacobson, K. A.; Klotz, K. N.; Linden, J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 2001, 53, 527-552. (Pubitemid 33136237)
14. Moro, S.; Gao, Z. G.; Jacobson, K. A.; Spalluto, G. Progress in the pursuit of therapeutic adenosine receptor antagonists. Med. Res. Rev. 2006, 26, 131-159. (Pubitemid 43334639)
15. Baraldi, P. G.; Cacciari, B.; Romagnoli, R.; Spalluto, G.; Mono-poli, A.; Ongini, E.; Varani, K.; Borea, P. A. 7-Substituted 5-ami-no-2-(2-furyl) pyrazolo[4, 3-e]-1, 2, 4-triazolo[1, 5-c]pyrimidines as A2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility. J. Med. Chem. 2002, 45, 115-126. (Pubitemid 34038546)
16. 2A adenosine receptor antagonists. J. Med. Chem. 1998, 41, 2126-2133. (Pubitemid 28308630)
17. 2A adenosine antagonists. J. Med. Chem. 1996, 39, 1164-1171.
18. 3 adenosine receptor antagonists. J. Med. Chem. 1999, 42, 4473-4478. (Pubitemid 29530002)
19. 3 adenosine receptor antagonists: Influence of the chain at N8 pyrazole nitrogen. J. Med. Chem. 2000, 43, 4768-4780. (Pubitemid 32002688)
20. 3 adenosine receptor antagonists. J. Med. Chem. 2002, 45, 770-780. (Pubitemid 34173930)
21. 3 adenosine receptor antagonist. J. Med. Chem. 2002, 45, 3579-3582. (Pubitemid 34856098)
22. 2B adenosine receptor subtypes: a molecular modeling investigation. J. Med. Chem. 2003, 46, 4287-96. (Pubitemid 37153010)
23. 3 adenosine receptor antagonists: new insight into structure activity relationship and receptor antagonist recognition. J. Med. Chem. 2010, 53, 3361-3375.
24. 2A receptor antagonists: actions on Parkinson's disease models. Eur. J. Pharmacol. 2005, 512, 157-164. (Pubitemid 40544349)
25. 2A receptor antagonists: comparison of three core heterocycles. Bioorg. Med. Chem. Lett. 2004, 14, 4831-4834. (Pubitemid 39165576)
26. 2A receptor antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 4809-4813. (Pubitemid 41354811)
27. 2A adenosine receptor antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 511-515. (Pubitemid 40143117)
28. 2A receptor antagonists. Bioorg. Med. Chem. Lett. 2004, 14, 4835-4838. (Pubitemid 39165577)
29. 2A receptor antagonists. J. Med. Chem. 2004, 47, 6218-6229. (Pubitemid 39587246)
30. 2A receptor antagonists. J. Med. Chem. 2005, 48, 2009-2018. (Pubitemid 40396328)
31. 2A selective adenosine receptor antagonist. Br. J. Pharmacol. 1995, 115, 1096-1102.
32. DeZwart, M.; Vollinga, R. C.; Beukers, M. W.; Sleegers, D. F.; von Frijtag Drabbe Kunzel, J. K.; De Groote, M.; IJzerman, A. P. Potent antagonists for the human adenosine A2B receptor. Derivatives of the triazolotriazine adenosine receptor antagonist ZM241385 with high affinity. Drug Dev. Res. 1999, 48, 95-103. (Pubitemid 30027326)
33. Ji, X. D.; Jacobson, K. A. Use of triazolotriazine [3H]-ZM241385 as a radioligand at recombinant human A2B adenosine receptors. Drug Des. Discovery 1999, 16, 217-226.
34. Pastorin, G.; Federico, S.; Paoletta, S.; Corradino, M.; Cateni, F.; Cacciari, B.; Klotz, K. N.; Gao, Z. G.; Jacobson, K. A.; Spalluto, G.; Moro, S. Synthesis and pharmacological characterization of a new series of 5, 7-disubstituted [1, 2, 4]triazolo[1, 5-a] [1, 3, 5]triazine derivatives as adenosine receptor antagonists: a preliminary inspection of ligand-receptor recognition process. Bioorg. Med. Chem. 2010, 18, 2524-2536.
35. Caulkett, P. W. R.; Jones, G.; McPartlin, M.; Renshaw, N. D.; Stewart, S. K.; Wright., B. Adenine isosteres with bridgehead nitrogen. Part 1. Two independent syntheses of the [1, 2, 4]triazolo-[1, 5-a][1, 3, 5]triazine ring system leading to a range of substituents in the 2, 5 and 7 positions. J. Chem. Soc. Perkin Trans. 1, 1995, 801-808.
36. Lee, D. W.; Ha, H. J.; Lee, W. K. Selective mono Boc-protection of diamines. Synth. Commun. 2007, 37, 737-742.
37. 2A adenosine receptor bound to an antagonist. Science 2008, 322, 1211-1217.
38. 3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition. J. Med. Chem. 2009, 52, 7640-7652.
39. 3 adenosine receptor as versatile G protein-coupled receptor example to validate the receptor homology modeling technology. Curr. Pharm. Des. 2009, 15, 4069-4084.
40. Pastorin, G.; Federico, S.; Paoletta, S.; Corradino, M.; Cateni, F.; Cacciari, B.; Klotz, K.-N.; Gao, Z.-G.; Jacobson, K. A.; Spalluto, G.; Moro, S. Synthesis and pharmacological characterization of a new series of 5, 7-disubstituted-[1, 2, 4]triazolo[1, 5-a][1, 3, 5]triazine derivatives as adenosine receptor antagonists: A preliminary inspection of ligand-receptor recognition process. Bioorg.Med.Chem. 2010, 18 (7), 2524-2536.
41. Bruns, R. F.; Fergus, J. H.; Badger, E. W.; Bristol, J. A.; Santay, L. A.; Hartman, J. D.; Hays, S. J.; Huang, C. C. Binding of the Ar selective adenosine antagonist 8-cyclopentyl-1, 3-dipropyl-xanthine to rat brain membranes. Naunyn-Schmiedeberg's Arch. Pharmaco . 1987, 335, 59-63. (Pubitemid 17000917)
42. 2A adenosine receptor. Mo. Pharmaco. 1996, 48, 970-974.
43. 3 adenosine receptor. Mo. Pharmaco. 1994, 45, 978-982.
44. Klotz, K. N.; Hessling, J.; Hegler, J.; Owman, C.; Kull, B.; Fredholm, B. B.; Lohse, M. J. Comparative pharmacology of human adenosine receptor subtypes-characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedeberg's Arch. Pharmacol. 1998, 357, 1-9. (Pubitemid 28085115)
45. Klotz, K. N.; Cristalli, G.; Grifantini, M.; Vittori, S.; Lohse, M. J. Photoaffinity labeling of A1-adenosine receptors. J. Biol. Chem. 1985, 260 (14), 659-14664.
46. 2A adenosine receptor. J. Biol. Chem. 1995, 270, 13987-13997.
47. 2A adenosine receptor are required for ligand recognition. Mol. Pharmacol. 1996, 49, 683-691.
48. Linden, J. Calculating the dissociation constant of an unlabeled compound from the concentration required to displace radiolabel binding by 50%. J. Cyclic Nucleotide Res. 1982, 8, 163-172. (Pubitemid 13174393)
49. MOE (Molecular Operating Environment), version 2009.10; Chemical Computing Group Inc.: Montreal, Quebec, Canada, 2009; http://www.chemcomp.com.
50. Stewart, J. J. P. MOPAC 7; Fujitsu Limited: Tokyo, Japan, 1993
51. 0GOLD suite, version 1.3.2; Cambridge Crystallographic Data Centre: Cambridge; http://www.ccdc.cam.ac.uk.
52. Ballesteros, J. A.; Weinstein, H. Integrated methods for the construction of three dimensional models and computational probing of structure-function relationships in G-protein coupled receptors. Methods Neurosci. 1995, 25, 366-428.
53. Halgren, T. A.; Myrphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, W. T. Glide: a new approach for rapid, accurate docking and scoring 1 methods and assessment of docking accuracy. J. Med. Chem. 2004, 47, 1739-1749. (Pubitemid 38380917)
54. Korb, O.; Stutzle, T.; Exner, T. E. Empirical Scoring Functions for advanced Protein-Ligand Docking with PLANTS. J. Chem. Inf. Model 2009, 49, 84-96.